The FDA has taken a cautious, scientific, evidence-based approach to regulating mifepristone (Mifeprex) over the years. That approach contradicts the Trump administration's claim, according to an analysis of agency documents. The review is a qualitative analysis of the listed documents. The article was published by MedPage Today.